In QuotedData’s morning briefing 3 July 2025: JPMorgan Global Growth and Income dividend to rise. Crystal Amber’s Morphic Medical gets EU approval.

• JPMorgan Global Growth and Income (JGGI) has decided on its dividend for the financial year ended 30 June 2026. There will be four quarterly payments of 5.75p to make a total of 23.0p, that is 0.9% higher than FY25’s dividend. The dividend is supposed to be based on 4% of the financial year end NAV, which fell by 3.1% year-on-year. However, the board wants to keep growing the dividend and the percentage will be a bit higher this year. [QD comment, James Carthew: So, JGGI gets to keep its record of dividend growth despite a fall in its NAV. The numbers here are too small to worry about, but, what would happen next year if the NAV falls again?]
• Crystal Amber (CRS) says its Morphic Medical subsidiary has secured European regulatory approval for its non-surgical, non-drug obesity and diabetes treatment. [QD comment, James Carthew: I cannot help thinking that the potential market for this is massively smaller than it was a couple of years ago, before the rapid growth in weight-loss drugs.]

We also have:

Murray Income board launches surprise strategic review

Seraphim’s June newsletter notes NATO win for ICEYE

Gresham House Energy Storage signs deal, half its revenues locked in

Did you see from yesterday?

Monks chairman reflects on another year of underperformance

Baker Steel flags uplift from Prognoz silver sale

Schroder BSC Social Impact is considering its future